Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan bought 22,901 shares of the firm’s stock in a transaction that occurred on Thursday, October 19th. The shares were acquired at an average price of $22.79 per share, with a total value of $521,913.79. Following the acquisition, the insider now owns 5,820,513 shares of the company’s stock, valued at $132,649,491.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) traded up 1.36% during trading on Monday, hitting $23.88. The company had a trading volume of 91,208 shares. Pulse Biosciences, Inc has a 52 week low of $5.20 and a 52 week high of $39.50. The stock’s 50-day moving average price is $18.62 and its 200 day moving average price is $24.70. The company’s market capitalization is $342.30 million.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, July 27th. The company reported ($0.43) EPS for the quarter.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/insider-buying-pulse-biosciences-inc-plse-major-shareholder-buys-22901-shares-of-stock.html.

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $325,000. TIAA FSB bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $943,000. OxFORD Asset Management LLP bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $310,000. California Public Employees Retirement System bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $297,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $529,000. 9.55% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Insider Buying and Selling by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.